‘Can you manufacture consistently?’ The big question in regenerative medicine

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/LuminaStock)
(Image: Getty/LuminaStock)

Related tags: Regenerative medicine, Novartis, Celgene

Regenerative medicine raised $13.3bn in funds during 2018 but investors question whether treatments can be manufactured consistently, according to AMR annual report.

For the regenerative medicine industry, 2018 will go down as “one of the most exciting for [the industry] thus far​,” due to greater investment and M&A activity, the Alliance for Regenerative Medicine (ARM) stated in its annual report.

The sector, including cell and gene therapies, and tissue engineering, attracted $13.3bn (€11.82bn) of investment – representing an increase of 73% against 2017 figures.

During 2018, M&A activity saw large pharma companies make investments in the acquisition of smaller regenerative medicines companies, such as the acquisition of June by Celgene​ for $9bn and AveXis being bought by Novartis​ for $8.7bn.

The report identified that there were 1,028 clinical trials for regenerative therapies ongoing globally, at the end of 2018.

Concerns for the industry

Despite the industry posting positive figures on the amount of investment raised in 2018, ARM’s report featured insight from Maria Fardis, CEO of Iovance​ Biotherapeutics, who suggested investors are concerned about manufacturing capabilities.

“I think the question [investors have] is, can you manufacture? Can you manufacture consistently?” ​she said. “They’re like, show me the data and let me assess the data. I also think investors are becoming savvier in that they have their own analysts.”

In the report, Christopher Vann, COO of Autolus Therapeutics, concurred with Fardis on companies in the space needing to refine their manufacturing process quickly. He stated, “The realisation today is that you need to fix your manufacturing process before you enter registration studies.”

However, Vann noted that he was encouraged by what he saw as the “maturation of the supply network”​, which he believes will see ‘fast followers’ have an easier time when it comes to constructing their manufacturing processes and creating a reliable commercial supply.

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more